Ampullary carcinomas represent less than 1% of all gastrointestinal malignancies with an incidence of approximately 6 cases per 1 million. Histologic examination and immunohistochemistry have been traditionally used to categorize ampullary tumors into intestinal, pancreatobiliary or mixed subtypes. Intestinal-subtype tumors may exhibit improved survival versus the pancreatobiliary subtype, although studies on the prognostic value of immunomorphologic classification have been inconsistent. Genomic classifiers hold the promise of greater reliability, while providing potential targets for precision oncology. Multi-institutional collaboration will be necessary to better understand how molecular classification can guide type and sequencing of multimodality therapy.
壶腹癌在所有胃肠道恶性肿瘤中占比不足1%,年发病率约为百万分之六。传统上通过组织学检查和免疫组化技术将壶腹肿瘤分为肠型、胰胆管型及混合型亚型。相较于胰胆管亚型,肠型肿瘤可能具有更好的生存预后,但关于免疫形态学分型预后价值的研究结论尚不一致。基因组分类器有望提供更可靠的预后判断,同时为精准肿瘤学提供潜在治疗靶点。未来需要通过多机构协作,进一步明确分子分型如何指导多模式治疗的方案选择与序贯策略。
Ampullary Adenocarcinoma: A Review of the Mutational Landscape and Implications for Treatment